If you scroll way down you'll see on the 10K a Number 8.
If you scroll way down you'll see on the 10K a Number 8. It basically says, as I understand it, that they will start recognizing that revenue with in the next 12 months assuming some number of years they expect the license to be alive. So for example, instead of recognizing the half a mil now in one shot, if they decide the license will last 500 years they will recognize $1000 a year for those 500 years. I'd guess there's some guidelines per GAAP that lays out how many years you can actually claim the revenue (less than 500 !).
I think they did the same thing with the revenue from the Canada deal. I think it was over something like 27 years. Could be wrong.
The fun part seems to be that there doesn't appear to be any way to know how that revenue is actually spent that I can tell ! It's just reported on the financials as revenue each year over the number of years they pick. And why was nothing reported in the year it was paid ? If I got paid I had to report it in that year or else.
I'm no CPA but I did run a sizeable company and read a lot of financials. I'd ask my CPA to read into this but he costs a $200 an hour !
The next question needs to be, " If the $500K was paid, how do the shareholders know how those funds are spent" ? For some reason they seem to be trying to defer revenues. If it's on the up and up, there must be a reason and I'd like to know it. Otherwise, funny business ? Nah !
Also, if you got an infusion of half a mil, why would you be doing $33,000 toxic loans ? I could guess. Is it because the big 3 (George, Jr., and Barry) get their ownership percentages covered while we get diluted by those actions so they are no worse off ? If they spend cash, they seem to be in the same boat as us.
My country club is full of CPA's and lawyers. I have to track some of them down and get some guidance. Some are semi retired sharks looking for something to do between trips to their various homes while on their Netjets.
All of this are my guesses and opinions so far. Don't take too much stock in it, but please do let me know what you think and what you find out.
2
Coates International (COTE) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...
Continue Reading
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue Reading
Top 5 Most Recently Viewed Articles
Investigation Overview for Voyager Therapeutics Investors Pomerantz LLP is currently exploring possible claims on behalf of investors in Voyager Therapeutics, Inc. (NASDAQ: VYGR). This exploration arises from concerns surrounding the company’s recent announcements and operational strategies. Details of the Investigation The inquiry focuses on whether Voyager and some of...
Continue Reading
Subway Announces Exciting Promotion for Air Travelers On January 27, a significant change is happening for travelers, especially for those who dread sitting in the middle seat of a plane. With a popular airline ending its open seating policy, millions are gearing up for assigned seating. This means that many passengers might find themselves in the middle seat, which is...
Continue Reading
Expanse Studios Shines at Industry Summit Expanse Studios, a cutting-edge gaming developer and a subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), has made a significant impression at the recent SBC Summit Lisbon. This event attracted around 25,000 attendees, featuring a mix of gaming innovators and industry experts, all eager to explore what's next in the gaming...
Continue Reading
Introducing the Preservica Academy for Digital Preservation Preservica Inc. has unveiled its exciting new initiative, Preservica Academy, dedicated to enhancing the skills of professionals and beginners in the realm of digital preservation. This innovative program focuses on Active Digital Preservation™, aiming to ensure the long-term accessibility and integrity of...
Continue Reading
Notification of Class Action Lawsuit for Seritage Growth Properties Levi & Korsinsky, LLP is reaching out to inform investors of Seritage Growth Properties (NYSE: SRG) regarding an ongoing class action securities lawsuit. This case marks an important development for those affected by alleged securities fraud. Overview of the Class Action Lawsuit This lawsuit is centered...
Continue Reading
